PFIZER’S CTI REQUESTS PROPOSALS FOR BIOTHERAPEUTIC AND SMALL-MOLECULE TARGETS

Pre-Proposal Deadline: October 7, 2016

Pfizer’s Centers for Therapeutic Innovation, or CTI, is a unique program that collaborates with leading academic medical centers, the NIH, and foundations to speed the translation of novel targets to the clinic.

Advantages to Collaborating with CTI
A partnership with CTI may include collaborative use of Pfizer’s technologies, publishing rights, and financial awards in the form of milestone and royalty payments for successful programs, in addition to providing appropriate funds for carrying out the collaborative work.

Foundations collaborating with CTI include:
• Alliance for Lupus Research
• Alzheimer’s Drug Discovery Foundation
• Crohn’s and Colitis Foundation of America
• Foundation for Sarcoidosis Research
• Juvenile Diabetes Research Foundation
• Jeffrey Modell Foundation

Pre-proposal Submission Process
Submission entails a brief, non-confidential 2-3 page overview of the target, mechanism (including evidence for disease linkage), and the proposed therapeutic drug. At a high level, the pre-proposal should suggest how the therapeutic hypothesis could be tested in the clinic.

For Information
Please contact Mary Faris (Mary.Faris@pfizer.com) or Manjula Donepudi (mdonepudi@mail.rockefeller.edu)

All researchers and clinicians whose work meets these criteria are invited to apply. Please submit pre-proposals to Manjula Donepudi (mdonepudi@mail.rockefeller.edu) by October 7, 2016.

What We Look For

• **Strong Project Rationale**, demonstrated association between target biology and disease mechanism
• **Novel drug targets** with potential to lead to differentiated drugs
• **Link between target pathway and human disease**
• **Ability to Address Unmet Medical Needs**
• **Feasibility**: tractable target, discovery/ development plan

Modalities

• **Large Molecules** (antibodies, proteins, peptides, ADCs, Fusions) or **Small Molecules** (target classes include kinases, GPCRs, ion channels, transporters, serine hydrolases, and epigenetic targets)

Therapeutic Areas of Interest for Fall 2016

• **Oncology**: Immuno-oncology, epigenetic targets, novel tumor specific cell surface antigens, and targets identified by unique insights in tumor biology
• **Inflammation and Immune disorders**: Crohn’s and Colitis, Gastrointestinal disorders, NASH and Rheumatoid Arthritis
• **Cardiovascular and metabolic diseases**: NAFLD/NASH, heart failure and Obesity/Eating Disorders
• **Neuroscience**: neurodegenerative disorders with a primary focus on Alzheimer’s Disease and Parkinson’s Disease (non A beta therapies), Huntington’s disease and chronic neuroinflammation mechanisms
• **Rare monogenic genetic diseases**: Hematologic, neuromuscular, pulmonary, and inherited metabolic/endocrine diseases